The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells

International Journal of Oncology

Volumn 31, Issue 4, 2007, Pages 803-811

  Nakamura, Tomoyuki ^a   Tanaka, Kazuhiro ^a   Matsunobu, Tomoya ^a   Okada, Takamitsu ^a   Nakatani, Fumihiko ^a   Sakimura, Riku ^a   Hanada, Masuo ^a   Iwamoto, Yukihide ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Apoptosis; Bortezomib; Ewing's family tumors; Multi drug resistance; Proteasome inhibitor

Indexed keywords

BORONIC ACID DERIVATIVE; BORTEZOMIB; CDKN1B PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; GLYCOPROTEIN P; HISTONE DEACETYLASE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; PROTEASOME; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE; SIGNAL PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; EWING SARCOMA; GENETICS; HUMAN; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BORONIC ACIDS; CELL CYCLE; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG RESISTANCE, NEOPLASM; HISTONE DEACETYLASES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, NUDE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEINS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SARCOMA, EWING'S; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 35848931009     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.4.803     Document Type: Article

References (35)

1. Grovas A, Fremgen A, Rauck A, et al: The National Cancer Data Base report on patterns of childhood cancers in the United States. Cancer 80: 2321-2332, 1997. (Pubitemid 28007404)
2. Iwamoto Y: Diagnosis and treatment of Ewing's sarcoma. Jpn J Clin Oncol 37: 79-89, 2007.
3. Cotterill SJ, Ahrens S, Paulussen M, et al: Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 18: 3108-3114, 2000.
4. Shankar AG, Ashley S, Craft AW and Pinkerton CR: Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. Med Pediatr Oncol 40: 141-147, 2003. (Pubitemid 36110274)
5. Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ and Denny CT: A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 6: 146-151, 1994. (Pubitemid 24188594)
6. Delattre O, Zucman J, Plougastel B, et al: Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359: 162-165, 1992.
7. May WA, Gishizky ML, Lessnick SL, et al: Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci USA 90: 5752-5756, 1993.
8. Matsumoto Y, Tanaka K, Nakatani F, Matsunobu T, Matsuda S and Iwamoto Y: Downregulation and forced expression of EWS-Fli1 fusion gene results in changes in the expression of G(1)regulatory genes. Br J Cancer 84: 768-775, 2001. (Pubitemid 32275649)
9. Tanaka K, Iwakuma T, Harimaya K, Sato H and Iwamoto Y: EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest 99: 239-247, 1997.
10. WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem 278: 15105-15115, 2003.
11. Matsunobu T, Tanaka K, Matsumoto Y, et al: The prognostic and therapeutic relevance of p27kip1 in Ewing's family tumors. Clin Cancer Res 10: 1003-1012, 2004.
12. Maki CG and Howley PM: Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol Cell Biol 17: 355-363, 1997.
13. Pagano M, Tam SW, Theodoras AM, et al: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682-685, 1995.
14. Pagano M: Cell cycle regulation by the ubiquitin pathway. FASEB J 11: 1067-1075, 1997.
15. King RW, Deshaies RJ, Peters JM and Kirschner MW: How proteolysis drives the cell cycle. Science 274: 1652-1659, 1996.
16. Hatakeyama S and Nakayama KI: Ubiquitylation as a quality control system for intracellular proteins. J Biochem 134: 1-8, 2003.
17. Chauhan D, Uchiyama H, Akbarali Y, et al: Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87: 1104-1112, 1996.
18. Hideshima T, Richardson P, Chauhan D, et al: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076, 2001.
19. Almond JB and Cohen GM: The proteasome: a novel target for cancer chemotherapy. Leukemia 16: 433-443, 2002.
20. Cavo M: Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia 20: 1341-1352, 2006.
21. Bross PF, Kane R, Farrell AT, et al: Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 10: 3954-3964, 2004.
22. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609-2617, 2003.
23. Goy A, Younes A, McLaughlin P, et al: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23: 667-675, 2005.
24. Kondagunta GV, Drucker B, Schwartz L, et al: Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 22: 3720-3725, 2004. (Pubitemid 41095212)
25. Maki RG, Kraft AS, Scheu K, et al: A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer 103: 1431-1438, 2005. (Pubitemid 40410740)
26. Okada T, Tanaka K, Nakatani F, et al: Involvement of Pglycoprotein and MRP1 in resistance to cyclic tetrapeptide sub-family of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells. Int J Cancer 118: 90-97, 2006.
27. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J and Elliott PJ: Proteasome inhibition measurements: clinical application. Clin Chem 46: 673-683, 2000.
28. Tanaka K, Iwamoto Y, Noguchi Y, Oda Y and Sugioka Y: The establishment and characterization of a peripheral neuroepithelioma cell line in soft tissue of extremity. Lab Invest 72: 237-248, 1995.
29. Matsunobu T, Tanaka K, Nakamura T, et al: The possible role of EWS-Fli1 in evasion of senescence in Ewing family tumors. Cancer Res 66: 803-811, 2006.
30. Ling YH, Liebes L, Zou Y and Perez-Soler R: Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 278: 33714-33723, 2003.
31. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234, 2006.
32. Fujita T, Washio K, Takabatake D, et al: Proteasome inhibitors can alter the signaling pathways and attenuate the P-glyco-protein-mediated multidrug resistance. Int J Cancer 117: 670-682, 2005. (Pubitemid 41504558)
33. Maki CG: Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2. J Biol Chem 274: 16531-16535, 1999. (Pubitemid 129526411)
34. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE and Gottesman MM: P-glycoprotein: from genomics to mechanism. Oncogene 22: 7468-7485, 2003.
35. Kruh GD and Belinsky MG: The MRP family of drug efflux pumps. Oncogene 22: 7537-7552, 2003.